JP at large: Some odd patient problems

An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.

Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.

The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.

Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.

As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.

Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.

In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.

In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.